OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Help
Advanced
Search
9
Results
Show all
Save search
Copy query
Show results for
Unknown
(9)
Release Date
2022
(2)
2016
(2)
2019
(1)
2018
(1)
2004
(1)
2003
(1)
2002
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Structural differences among hemagglutinins of influenza A virus subtypes are reflected in their antigenic architecture: analysis of H9 escape mutants.
Not available
S-EPMC303415
|
biostudies-literature
Cite
Neurovirulence in mice of H5N1 influenza virus genotypes isolated from Hong Kong poultry in 2001.
Not available
S-EPMC149508
|
biostudies-literature
Cite
Fast-Processable Non-Flammable Phthalonitrile-Modified Novolac/Carbon and Glass Fiber Composites.
Not available
S-EPMC9699085
|
biostudies-literature
Cite
Emergence of multiple genotypes of H5N1 avian influenza viruses in Hong Kong SAR.
Not available
S-EPMC124404
|
biostudies-literature
Cite
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.
Not available
S-EPMC6438948
|
biostudies-literature
Cite
Distance from sub-Saharan Africa predicts mutational load in diverse human genomes.
Not available
S-EPMC4743782
|
biostudies-literature
Cite
Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma.
Not available
S-EPMC4803452
|
biostudies-literature
Cite
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.
Not available
S-EPMC11651366
|
biostudies-literature
Cite
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
Not available
S-EPMC5819601
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets